Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERUSALEM, May 1, 2013 -- /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its article titled, “Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled Type 1 diabetes: a pilot study,” has been published in PLOS ONE, an international, peer-reviewed, open-access journal which covers primary scientific and medical research.
The article details the results of a clinical study, in which ORMD-0801 was administered to patients with unstable Type 1 diabetes, in conjunction with their regular anti-diabetes treatment regimens. These patients typically suffer from unpredictable and frequent swings in their blood sugar levels, which often demand hospitalization and severely disrupt their quality of life. The addition of ORMD-0801 was well tolerated and significantly stabilized blood sugar levels in this patient group. A significant drop in the frequency of above-normal blood sugar readings was observed, as well as a decrease in overall blood sugar levels throughout the day.
“These published results lay the groundwork for further study of the potential of ORMD-0810 as a treatment that can considerably aid a patient population resistant to standard anti-diabetes treatment protocols,” stated Oramed CEO Nadav Kidron.
The article can be viewed on PLOS ONE’s site, the content of which is not part of this press release, at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059524
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company’s corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com.
Help employers find you! Check out all the jobs and post your resume.
